Despite wide use of anti-vascular endothelial growth factor (VEGF) therapy for many solid cancers, most individuals become resistant to this therapy, leading to disease progression. Therefore, new biomarkers and strategies for blocking adaptive resistance of cancer to anti-VEGF therapy are needed. As described here, we demonstrate that cancer-derived small extracellular vesicles package increasing quantities of VEGF and other factors in response to anti-VEGF therapy. The packaging process of VEGF into small extracellular vesicles (EVs) is mediated by the tetraspanin CD63. Furthermore, small EV-VEGF (eVEGF) is not accessible to anti-VEGF antibodies and can trigger intracrine VEGF signaling in endothelial cells. eVEGF promotes angiogenesis and enhances tumor growth despite bevacizumab treatment. These data demonstrate a mechanism where VEGF is partitioned into small EVs and promotes tumor angiogenesis and progression. These findings have clinical implications for biomarkers and therapeutic strategies for ovarian cancer.Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.
About The Expert
Shaolin Ma
Lingegowda S Mangala
Wen Hu
Emine Bayaktar
Akira Yokoi
Wei Hu
Sunila Pradeep
Sanghoon Lee
Paul D Piehowski
Alejandro Villar-Prados
Sherry Y Wu
Michael H McGuire
Olivia D Lara
Cristian Rodriguez-Aguayo
Christopher J LaFargue
Nicholas B Jennings
Karin D Rodland
Tao Liu
Vikas Kundra
Prahlad T Ram
Sundaram Ramakrishnan
Gabriel Lopez-Berestein
Robert L Coleman
Anil K Sood
References
PubMed